Gemcitabine and carboplatin in combination for the treatment of advanced, metastatic, non-small cell lung cancer

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 18, 2007, Pages 3265-3275

  Nagel, Sylke ^a   Califano, Raffaele ^b   Thatcher, Nicholas ^c   Blackhall, Fiona ^c  

^a Krankenhaus Martha Maria   (Germany)

^b SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^c CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

carboplatin; chemotherapy; gemcitabine; non small cell lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE;

AREA UNDER THE CURVE; COMPARATIVE STUDY; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METASTASIS; PATHOLOGY; QUALITY OF LIFE; REVIEW; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; HUMANS; LUNG NEOPLASMS; QUALITY OF LIFE; SURVIVAL RATE;

EID: 40949087360     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.8.18.3265     Document Type: Article

References (55)

1. Chemotherapy for non-small cell lung cancer. Non-small Cell Lung Cancer Collaborative Group. Cochrane Database Syst. Rev. (2000) (2):CD002139.
2. CULLEN MH, BILLINGHAM LJ, WOODROFFE CM et al.: Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J. Clin. Oncol. (1999) 17(10):3188-3194.
3. BLACKHALL FH, SHEPHERD FA, ALBAIN KS: Improving survival and reducing toxicity with chemotherapy in advanced non-small cell lung cancer: a realistic goal? Treat Respir. Med. (2005) 4(2):71-84.
4. NOBLE S, GOA KL: Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs (1997) 54(3):447-472.
5. STORNIOLO AM, ALLERHEILIGEN SR, PEARCE HL: Preclinical, pharmacologic, and Phase I studies of gemcitabine. Semin. Oncol. (1997) 24 (2 Suppl. 7):S7-2-S7-7.
6. WANG LR, HUANG MZ, XU N et al.: Pharmacokinetics of gemcitabine in Chinese patients with non-small-cell lung cancer. J. Zhejiang Univ. Sci. B (2005) 6(5):446-450.
7. WOLOSCHUK DM, PRUEMER JM, CLUXTON RJ Jr: Carboplatin: a new cisplatin analog. Drug Intell. Clin. Pharm. (1988) 22(11):843-849.
8. HARRAP KR: Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat Rev. (1985) 12(Suppl. A):21-33.
9. HARRAP KR: Initiatives with platinum-and quinazoline-based antitumor molecules-Fourteenth Bruce F. Cain Memorial Award Lecture. Cancer Res. (1995) 55(13):2761-2768.
10. VAN ECHO DA, EGORIN MJ, AISNER J: The pharmacology of carboplatin. Semin. Oncol. (1989) 16(2 Suppl. 5):1-6.
11. GO RS, ADJEI AA: Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J. Clin. Oncol. (1999) 17(1):409-422.
12. CALVERT AH, NEWELL DR, GUMBRELL LA et al.: Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol. (1989) 7(11):1748-1756.
13. BERGMAN AM, RUIZ VAN HAPEREN VW, VEERMAN G, KUIPER CM, PETERS GJ: Synergistic interaction between cisplatin and gemcitabine in ovarian and colon cancer cell lines. Adv. Exp. Med. Biol. (1994) 370:139-143.
14. VAN MOORSEL CJ, PINEDO HM, VEERMAN G et al. : Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br. J. Cancer (1999) 80(7):981-990.
15. CRUL M, VAN WAARDENBURG RC, BOCXE S et al. : DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin. Biochem. Pharmacol. (2003) 65(2):275-282.
16. PETERS GJ, BERGMAN AM, RUIZ VAN HAPEREN VW et al.: Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin. Oncol. (1995) 22(4 Suppl. 11):72-79.
17. BAJETTA E, STANI SC, DE CANDIS D et al. : Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer. Ann. Oncol. (2003) 14(2):242-247.
18. VAN MOORSEL CJ, KROEP JR, PINEDO HM et al.: Pharmacokinetic schedule fi nding study of the combination of gemcitabine and cisplatin in patients with solid tumors. Ann. Oncol. (1999) 10(4):441-448.
19. GANDARA DR, LAU DH, LARA PN Jr, EDELMAN MJ: Gemcitabine/carboplatin combination regimens: importance of dose schedule. Oncology (Williston Park) (2000) 14(7 Suppl. 4):26-30.
20. SHEPHERD FA, ABRATT R, CRINO L et al.: The infl uence of gemcitabine and cisplatin schedule on response and survival in advanced non-small cell lung cancer. Lung Cancer (2000) 30(2):117-125.
21. KROEP JR, PETERS GJ, VAN MOORSEL CJ et al.: Gemcitabine-cisplatin: a schedule fi nding study. Ann. Oncol. (1999) 10(12):1503-1510.
22. CARMICHAEL J, ALLERHEILIGEN S, WALLING J: A Phase I study of gemcitabine and carboplatin in non-small cell lung cancer. Semin. Oncol. (1996) 23(5 Suppl. 10):55-59.
23. IAFFAIOLI RV, TORTORIELLO A, FACCHINI G et al. : Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non-small-cell lung cancer. J. Clin. Oncol. (1999) 17(3):921-926.
24. NG EW, SANDLER AB, ROBINSON L, EINHORN LH: A Phase II study of carboplatin plus gemcitabine in advanced non-small-cell lung cancer (NSCLC): a hoosier oncology group study. Am. J. Clin. Oncol. (1999) 22(6):550-553.
25. MASOTTI A, ZANNINI G, GENTILE A, MORANDINI G: Activity of gemcitabine and carboplatin in advanced non-small cell lung cancer: a Phase II trial. Lung Cancer (2002) 36(1):99-103.
26. GAJRA A, MEHDI SA, KIRSHNER J, NEWMAN N, GRAZIANO SL: Phase I study of gemcitabine and carboplatin in advanced non-small cell lung carcinoma. Lung Cancer (2001) 32(2):189-196.
27. THOMAS P, ROBINET G, FERRI-DESSENS RM et al. : Phase I trial of gemcitabine and carboplatin in metastatic non-small-cell lung cancer: a Groupe Francais de Pneumo-Cancerologie Study. Lung Cancer (2002) 36(2):191-198.
28. PARENTE B, BARROSO A, CONDE S, GUIMARAES T, SEADA J: A prospective study of gemcitabine and carboplatin asfi rst-line therapy in advanced non-small cell lung cancer: toxicity of a three-versus a four-week schedule. Semin. Oncol. (2001) 28(3 Suppl. 10):10-14.
29. KORTSIK C, ALBRECHT P, ELMER A: Gemcitabine and carboplatin in patients with locally advanced or metastatic non-small cell lung cancer: a prospective Phase II study. Lung Cancer (2003) 40(1):85-90.
30. MAESTU I, GOMEZ-ALDARAVI L, TORREGROSA MD et al.: Gemcitabine and low dose carboplatin in the treatment of elderly patients with advanced non-small cell lung cancer. Lung Cancer (2003) 42(3):345-354.
31. MAZZANTI P, MASSACESI C, ROCCHI MB et al.: Randomized, multicenter, Phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer (2003) 41(1):81-89.
32. YAMAMOTO N, NAKAGAWA K, UEJIMA H et al. : Randomized Phase II study of carboplatin/gemcitabine versus vinorelbine/gemcitabine in patients with advanced nonsmall cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) 0104. Cancer (2006) 107(3):599-605.
33. THOMAS P, ROBINET G, GOUVA S et al. : Randomized multicentric Phase II study of carboplatin/gemcitabine and cisplatin/vinorelbine in advanced non-small cell lung cancer GFPC 99-01 study (Groupe francais de pneumo-cancerologie). Lung Cancer (2006) 51(1):105-114.
34. EDELMAN MJ, CLARK JI, CHANSKY K et al. : Randomized Phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel. Clin. Cancer Res. (2004) 10(15):5022-5026.
35. SCHUETTE W, BLANKENBURG T, SCHNEIDER CP et al.: Randomized, multicenter, open-label Phase II study of gemcitabine plus single-dose versus split-dose carboplatin in the treatment of patients with advanced-stage non-small-cell lung cancer. Clin. Lung Cancer (2006) 8(2):135-139.
36. SEDERHOLM C, HILLERDAL G, LAMBERG K et al. : Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. J. Clin. Oncol. (2005) 23(33):8380-8388.
37. GRIGORESCU AC, DRAGHICI IN, NITIPIR C, GUTULESCU N, CORLAN E: Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-small-cell lung cancer (NSCLC) stages III and IV: a Phase III randomised trial. Lung Cancer (2002) 37(1):9-14.
38. ZATLOUKAL P, PETRUZELKA L, ZEMANOVA M et al. : Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a Phase III randomized trial. Lung Cancer (2003) 41(3):321-331.
39. DANSON S, MIDDLETON MR, O'BYRNE KJ et al. : Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. Cancer (2003) 98(3):542-553.
40. RUDD RM, GOWER NH, SPIRO SG et al. : Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a Phase III randomized study of the London Lung Cancer Group. J. Clin. Oncol. (2005) 23(1):142-153.
41. LE CHEVALIER T, SCAGLIOTTI G, NATALE R et al.: Effi cacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer (2005) 47(1):69-80.
42. PUJOL JL, BARLESI F, DAURES JP: Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of Phase III randomized trials. Lung Cancer (2006) 51(3):335-345.
43. D'ADDARIO G, PINTILIE M, LEIGHL NB et al.: Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J. Clin. Oncol. (2005) 23(13):2926-2936.
44. CHU Q, VINCENT M, LOGAN D, MACKAY JA, EVANS WK: Taxanes as fi rst-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline. Lung Cancer (2005) 50(3):355-374.
45. JIANG J, LIANG X, ZHOU X, HUANG R, CHU Z: A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer (2007).
46. ARDIZZONI A, BONI L, TISEO M et al. : Cisplatin-versus carboplatin-based chemotherapy in fi rst-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J. Natl. Cancer Inst. (2007) 99(11):847-857.
47. BLACKHALL FH, TAYLOR P, ASHCROFT L et al. : A pragmatic, randomised study to compare the hospitalisation rates of two platinum-based outpatient regimens (gemcitabine/cisplatin vs. gemcitabine/carboplatin) in non-small cell lung cancer (NSCLC)-UK Swiss collaboration. J. Thoracic Oncology (2007) 2(8):S338.
48. SANDLER A, GRAY R, PERRY MC et al.: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. (2006) 355(24):2542-2550.
49. MANEGOLD C, VON PAWEL J, ZATLOUKAL P et al.: Randomised, double-blind multicentre Phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-na ï ve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC):BO17704. J. Clin. Oncol., 2007 ASCO Annual Meeting Proceedings Part I (2007) 25(18S):LBA7514.
50. BEPLER G, KUSMARTSEVA I, SHARMA S et al. : RRM1 modulated in vitro and in vivo effi cacy of gemcitabine and platinum in non-small-cell lung cancer. J. Clin. Oncol. (2006) 24(29):4731-4737.
51. HEINEMANN V, XU YZ, CHUBB S et al. : Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2 ′,2′-difl uorodeoxycytidine. Mol. Pharmacol. (1990) 38(4):567-572.
52. DAVIDSON JD, MA L, FLAGELLA M et al. : An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res. (2004) 64(11):3761-3766.
53. ROSELL R, DANENBERG KD, ALBEROLA V et al.: Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin. Cancer Res. (2004) 10(4):1318-1325.
54. REED E: Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev. (1998) 24(5):331-344.
55. OLAUSSEN KA, DUNANT A, FOURET P et al. : DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. (2006) 355(10):983-991.